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Abstract
Background: Previous studies have shown that the short arm of chromosome 5 (5p) exhibit
frequent genetic changes in invasive cervical carcinoma (CC), and that these changes arise early
during the carcinogenesis, in precancerous lesions. These data therefore suggest that loss of
candidate tumor suppressor genes located on 5p is associated with the development of CC.
However, the precise location of 5p deletions is not known.
Results: We performed a detailed deletion mapping of 5p in 60 cases of invasive CC. We found
that 60% of the tumors exhibit a 5p loss of heterozygosity (LOH). The patterns of LOH allowed
us to identify two minimal regions of deletions, one at 5p15.3 spanning a 5.5 cM genetic distance
and a second site of 7 cM at 5p15.2-15.3. In addition, we also identified 5p deletions in 16% lesions
of high-grade cervical intraepithelial neoplasia (CIN). 5p LOH was found in 63% of HPV 16 positive
tumors, while only 33% tumors with other HPV-types had 5p LOH. The differences in frequency
of 5p LOH between tumors harboring HPV16 in combination with other HPV types and tumors
harboring HPV16 DNA alone were significantly higher, suggesting a synergistic effect of high-risk
types in causing genomic instability.
Conclusion: These findings implicate the presence of tumor suppressor gene(s) on 5p relevant to
CC tumorigenesis.
Background
Converging points of evidence implicate infection by
high-risk human papilloma virus (HPV) types as a critical
etiologic factor in cervical tumorigenesis [1]. Epidemio-
logical and experimental data, however, show that only a
small fraction of HPV-infected cervical intraepithelial ne-
oplastic (CIN) lesions progress to invasive cervical carci-
noma (CC) [2]. These findings suggest somatic genetic
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mutations play a critical role in the initiation and progres-
sion of CC. Delineation of these genetic changes is crucial
to understanding the molecular basis of CC. A number of
genetic changes have been identified so far in invasive CC.
However, the precise mechanism of each of these genetic
alterations in the multi-step pathway of cervical tumor de-
velopment is largely unknown. The development of CC is
preceded by distinct morphological changes from normal
epithelium to carcinoma through low-grade and high-
grade squamous intraepithelial lesions (SILs). The genetic
basis of this progression is also poorly understood.
Cytogenetic and molecular genetic analyses have identi-
fied the short arm of chromosome 5, 5p, as frequently af-
fected by duplications and deletions in a high proportion
of CCs [3–6]. These findings suggest the presence of posi-
tively regulated amplified oncogenes and negatively regu-
lated tumor suppressor genes (TSGs) on this
chromosomal arm. Comparative genomic hybridization
(CGH), a molecular cytogenetic method that identifies
chromosomal gains and losses, and loss of heterozygosity
(LOH) studies have also demonstrated recurrent deletions
on the 5p in precancerous lesions [7–10]. Although, these
studies have identified 5p as a commonly affected region,
the precise site of deletion that harbor putative TSG is un-
known because of the lack of systematic and detailed de-
letion mapping studies.
To further characterize the 5p region in CC, we performed
a high-resolution deletion mapping in invasive cancer
and found that 60% of patients exhibit LOH. We identi-
fied two sites of minimal deletions at 5p15.3 and 5p15.2-
15.3 spanning 5.5 cM and 7 cM genetic distance, respec-
tively. We have also shown that the 5p15 region deletions
occur in 16% of high-grade CIN lesions. Here, we have
identified two sites of candidate tumor suppressor genes
and confirmed the previous reports that the 5p deletions
occur in a small proportion of precancerous lesions.
Figure 1
Identification of minimal deleted regions by high-resolution LOH mapping on 5p in invasive CC. Patterns of LOH. Thirty-six
tumors with 5p LOH are shown. A G-banded ideogram of chromosome 5 is shown on top. Thick horizontal line shown below
the ideogram represents the corresponding chromosomal region (scaled only approximately). Small vertical lines show STRP
markers on the thick horizontal line and their corresponding genetic map distances. The percentage of LOH is shown in hori-
zontal box below each STRP marker. The patterns of LOH are shown below. A horizontal line represents each tumor; Marker
region with LOH is shown by light shaded lines, and dark shaded lines show the retention of heterozygosity. Tumor numbers
are shown on left of horizontal lines. The thick light shaded line denoted on left with # represents 17 tumors that showed LOH of
the entire 5p. Thick black rectangles at the bottom indicate region of minimal deletion.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/3
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Results
Identification of two regions of minimal deletions at 
5p15.2-p15.3
Analysis of LOH in 60 invasive CCs using 20 STRP mark-
ers mapped to 5p showed deletions in 36 of 60 (60%) tu-
mors in at least one marker (Table 1). Of the 36 tumors
with LOH, 17 (47.2%) had LOH at all the informative
markers suggesting genetic monosomy of 5p (Fig. 1). The
patterns of LOH in the remaining 19 tumors that exhibit-
ed regional losses on 5p were used to map the common
deleted regions (Fig. 1). This has identified two minimal
deletions at 5p15.3 and 5p15.2-15.3 (Fig. 1 & Fig. 2). All
the tumors that defined the minimal deletions showed
more than 60% reduction in signal intensity in the delet-
ed alleles.
The distal 5p15.3 deletion spans the telomeric region en-
compassing D5S392, D5S678, and D5S417 markers in 32
tumors. Although two tumors (T-13 and T-49) showed
deletions of terminal marker D5S392 alone at 0 cM genet-
ic distance, which is the distal most marker on 5p, we con-
sidered the deletion boundaries defined by the proximal
marker D5S417 in tumors T-6 and T-105 (Fig. 1 & Fig. 2).
The second and proximal region of deletion spans 6 mark-
ers (D5S406, GATA82H02, D5S1455, D5S2054, D5S635
and D5S676), and was deleted in 28 tumors. The deletion
boundaries were defined proximally by the tumors T-59
and T-66, while the distal boundary was identified by the
tumors T-59 and T-114 (Fig. 1 & Fig. 2). All tumors that
showed 5p deletions fell within the two defined regions of
deletions, while 25 tumors exhibited deletions at both re-
gions. Thus, this analysis identified two discrete and close-
ly mapped sites of minimal deletions at 5p15.3 and
5p15.2-15.3, which were restricted to 5.5 cM and 7 cM ge-
netic distance, respectively.
Gene expression analysis of candidate tumor suppressor 
genes in CC cell lines
In an effort to identify the genes inactivated in the recur-
rent 5p deletions in CC, we identified candidate genes
with tumor suppressor function. Three genes were identi-
fied at the terminal 5p15.3 deletion. These include,
PDCD6, a protein that plays a role in T cell receptor-, FAS-
, and glucocorticoid-induced cell death [11]; TERT, a gene
that encodes a reverse transcriptase component of telom-
erase, dysfunction of which promotes chromosomal in-
stability [12]; and TRIP13, a thyroid hormone receptor
interacting protein that binds with the human papilloma-
virus type 16 (HPV16) E1 protein [13]. We have identified
POLS gene that encodes a DNA polymerase sigma, and
plays a role in DNA replication and sister chromatid cohe-
sion at the proximal minimal deleted region [14]. We per-
formed a semi-quantitative RT-PCR analysis of all four
genes (PDCD6, TERT, TRIP13, and POLS) in eight CC cell
lines and did not find evidence for lack of or down regu-
lated expression compared to normal cervix (Fig. 3).
5p deletions in relation to HPV
5p deletions did not show any significant differences with
age at diagnosis and stage of the tumor (data not shown).
Fifty-eight (96.7%) of the 60 tumors studied were positive
for HPV DNA. The remaining two tumors were HPV-neg-
Table 1: Frequency of LOH on 5p in cervical carcinoma
Chromosome Band Locus Genetic map position 
(in cM)
No. studied/ Informative LOH (%)
5p15.3 D5S392 0.0 60/39 21 (53.8)
D5S678 0.0 59/27 11 (40.7)
D5S417 5.5 59/28 15 (53.6)
D5S405 8.2 58/29 11 (37.9)
D5S2088 8.2 59/48 20 (41.7)
D5S406 10.7 60/39 17 (43.6)
GATA82H02 11.0 60/42 21 (50.0)
5p15.2 D5S1455 13.0 60/38 20 (52.6)
D5S2054 13.2 60/37 17 (45.9)
D5S635 13.8 60/40 18 (45.0)
D5S676 15.6 57/29 11 (37.9)
D5S1957 17.7 59/42 17 (40.5)
D5S208 18.0 60/40 13 (32.5)
D5S630 18.6 60/46 17 (37.0)
5p14 D5S432 21.4 58/42 16 (38.1)
D5S117 22.0 58/37 13 (35.1)
D5S416 27.9 59/46 18 (39.1)
D5S486 31.0 57/40 13 (32.5)
5p13.2 D5S419 39.5 60/48 18 (37.5)
5p11-12 D5S426 51.6 60/41 13 (31.7)Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/3
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ative. HPV 16 alone or in combination with other HPV
types was found in 46 tumors, while 12 tumors had other
HPV types including HPV 18. 5p LOH was found in 29 of
46 (63%) HPV 16 positive tumors, while only 4 of 12
(33%) tumors with other HPV-types had 5p LOH. The
two tumors that did not harbor HPV infection also had
LOH at 5p. These differences were found to be statistically
not significant (Chi square 4.93; p = 0.10). However,
when the analysis was restricted to HPV16 harboring tu-
mors, it was found that the patients harboring HPV16
DNA alone had 5p LOH in 20 of 36 (55.6%) tumors,
while the patients infected with HPV16 in combination
with other HPV types exhibited 9 of 10 (90%) LOH. This
difference was found to be statistically significant (Chi
square, 8.75; p = 0.05).
5p deletions occur at low frequency in precancerous le-
sions
To understand the role of 5p deletions in cervical cancer
progression, we evaluated LOH in 26 microdissected CIN
specimens (25 high-grade CINs and one low-grade CIN)
using four STRP markers (Table 2). Four of the 25 inform-
ative tumors had LOH at one or more markers. One low-
grade CIN did not show LOH. Thus, deletions at 5p iden-
tified in high-grade CINs suggest that these genetic altera-
tions occur prior to development of invasive carcinoma.
Discussion
Extensive genetic studies have documented frequent alter-
ations affecting various chromosomal regions in CC. LOH
and CGH analyses have consistently shown frequent loss
of genomic material in a number of chromosomal regions
Figure 2
Illustration of LOH of tumors representing minimal deletions at 5p15.3 (T-6) (left panel) and 5p15.3-15.2 (T-59) (right panel).
The STRP markers are shown above and the tumor numbers below of each panel. N, normal; T, tumor; Asterisks indicate
LOH. Reduction of signal intensity by 50% or more of one of the alleles in tumor DNA compared with the intensity of consti-
tutional alleles was considered LOH.
Figure 3
Multiplex RT-PCR analysis of expression of 5p candidate
genes in CC cell lines. Genes are shown on left; cell lines are
indicated on top; arrowhead indicates the PCR product of
actin gene used as control and arrow represents the indi-
cated gene. Note the complete lack of expression of TERT
and TRIP13 genes in normal cervix.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/3
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suggesting the presence of potential tumor suppressor
genes at these sites [4,6,15,16]. Of these, chromosome 5p
deletions have been noted to be very frequent in invasive
CC [5–7]. However, the locations of exact regions of LOH
are not known because of a lack of systematic and high-
resolution deletion mapping of the 5p region in CC. We
have previously identified that markers mapped to 5p15
regions are more frequently deleted [4,7]. To further char-
acterize the 5p deletions in CC, we performed a high-den-
sity LOH mapping in the present study. We found high
frequency of LOH and identified two minimal regions of
deletions at 5p15.3 and 5p15.2-15.3.
The 5p15.3 minimal deletion spans between 0–5.5 cM ge-
netic distance. Consistent with this pattern, the markers
D5S392 and D5S417 exhibited the highest frequency
(53.8% and 53.6%, respectively) of LOH among all the
tested loci. The genomic size of the 5p15.3 deletion inter-
val is approximately 3.2 Mb. A database search has identi-
fied three candidate genes, PDCD6, TERT, and TRIP13,
with suggestive tumor suppressor gene function. The pro-
grammed cell death gene, PDCD6, is a member of the
family of intracellular Ca2+-binding proteins and a part of
the apoptotic machinery controlled by T-cell receptor
(TCR), Fas, and glucocorticoid signals [11,17]. TERT en-
codes a reverse transcriptase required for the replication of
chromosome termini and plays a role in telomere elonga-
tion. Although telomerase expression is a hallmark of can-
cer, the mice lacking the RNA component of telomerase
(mTERC) exhibit progressive telomere shortening and
chromosomal instability associated with epithelial tu-
mors [12]. Consistent with the established role of this en-
zyme in cell immortalization and cancer pathogenesis
[18], we did not find expression in normal cervix while it
was abundantly present in all eight cell lines studied (Fig.
3). Recently, it has been shown that the hTERT amplifica-
tion and over expression is common in CC [19]. TRIP13,
thyroid receptor interacting protein 13, is a transcription
factor that regulates expression of a variety of specific tar-
get genes including the human papillomavirus type 16
(HPV16) E1 protein [13]. Similar to TERT, the TRIP13
also showed very low expression in normal cervix and
highly elevated levels of expression in CC cell lines (Fig.
3). Presence of these genes at the 5p15.3 interval suggests
that they may be target TSGs of these deletions in CC.
However, expression analysis of these genes did not pro-
vide evidence of down-regulation in CC cell lines.
The second site of minimal deletion at 5p15.2-15.3 be-
tween 10.7 and 17.7 cM genetic distance spans approxi-
mately 2.5 Mb genomic region. A database search has
identified  POLS, a topoisomerase-related function pro-
tein-4-1, gene that encodes polymerase (DNA directed)
sigma within the deleted region. The yeast homolog TRF4
plays a critical role in chromosome segregation by coordi-
nating between DNA replication and sister chromatid co-
hesion [14]. Analysis of expression of this gene in CC cell
lines did not show evidence of down regulation. Although
the genes tested so far showed no deregulated expression,
it remains to be seen whether any of these genes or the
others mapped to the minimal deleted regions are targets
of mutations in CC. However, the present study identified
two discrete sites of deletions at 5p15.3 and 5p15.2-15.3
that harbor putative TSGs important in CC development
providing a basis for their identification.
5p deletions also have been reported in precursor CIN le-
sions with the frequencies between 14.7 and 42% [7–10].
We have previously shown, in a different geographical
population, that 21% of CINs had 5p deletions. Based on
the follow-up studies, we suggested that 5p genetic dele-
tions might identify high-risk lesions for progression to
invasive cancer [7]. In a more recent study it was also
shown that the 5p deletions were significantly more fre-
quent in dysplasias that were recurrent compared to non-
recurrent dysplasias [9]. These data therefore suggest that
5p genetic alterations occur early in cervical carcinogene-
sis and they may be critical to the development of invasive
cancer. Supporting previous reports, in the present study,
we detected LOH at 5p15 in 16% of the high-grade CINs
(Table 2).
The role and mechanisms involved in high-risk HPV in-
duced genomic instability has been of a considerable
speculation [reviewed in ref. [20]]. High-risk HPV E6 and
E7 gene expression can independently immortalize vari-
ous human cell types in vitro. The E6 gene interacts with
p53 and an apoptotic protein BAK, followed by its degra-
dation, which results in chromosomal instability and re-
sistance to apoptosis [21,22]. The E7 protein interacts
with pRB followed by its degradation [23]. The p53 and
pRB proteins have been shown to play multiple roles in
cell growth and in genomic integrity. There have been
contradictory reports on targeted 5p deletions in relation
to HPV infection [5,24]. Ku and co-workers have shown
that 5p deletions occur in significantly high proportion of
CC infected with HPV 16 compared to low-risk HPVtypes
[5]. Contradictory to this, another study has shown that
5p deletions are independent of HPV16 and HPV18 infec-
Table 2: 5p LOH in cervical precancerous lesions
Locus No. of CINs 
studied
No.     
Informative
LOH (%)
D5S2088 25 22 1 (4.5%)
GATA82H02 24 17 3 (17.6%)
D5S1455 18 9 1 (11.1%)
D5S635 23 17 2 (11.8%)Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/3
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tion [24]. In the present study, we did not find any signif-
icant differences in 5p LOH between patients harboring
HPV16 and other HPV types. However, we found that pa-
tients harboring HPV16 in combination with other HPV
types showed significant increase in 5p loss compared to
patients harboring HPV16 alone. These data, therefore,
suggest that multiple high-risk HPV infections may have
synergistic effect in causing genomic instability. Thus, cur-
rently it is unclear the role of high-risk HPV types in caus-
ing 5p genomic instability. Further studies are needed to
address this question.
Conclusions
In summary, the present study confirms our previous ob-
servations that genetic loss of 5p is a common feature of
invasive CC. Here we identified two common sites of de-
letions that harbor candidate tumor suppressor genes on
this chromosomal arm and showed that multiple infec-
tion of high-risk HPV types may cause targeted genomic
instability at 5p. In addition, we have shown that the ge-
netic deletions on 5p occur early during the development
of CC in high-grade CIN lesions. Our identification of
minimal deletions on 5p and LOH in CINs has several po-
tential implications. First, it should facilitate the identifi-
cation of the target genes of importance in cervical
tumorigenesis. Second, it may provide critical genetic
markers for identifying cervical intraepithelial neoplasias
at high-risk to progression.
Methods
Tumor and normal tissues
We analyzed 60 tumor biopsies consisting of previously
untreated primary invasive CCs with the corresponding
peripheral blood samples, and 26 formalin-fixed and par-
affin-embedded CIN specimens. The tissues were ob-
tained from patients treated at the Instituto Nacional de
Cancerologia, Colombia after appropriate informed con-
sent and approval of the protocols by the institutional re-
view board. The invasive tumors were clinically classified
as FIGO stage IB (5 tumors), IIB (14 tumors), IIIB (37 tu-
mors), and IV (4 tumors). Histologically, 57 tumors were
classified as squamous cell carcinomas and 3 as adenocar-
cinomas. Twenty-five CIN specimens were classified as
high-grade and one as low-grade lesions. Eight CC cell
lines SiHa, SW756, C-4I, Ca Ski, C-33A, HT-3, MS751 and
ME-180 were obtained from the American Type Culture
Collection (ATCC, Manassas, VA), and were grown in cul-
ture according to the supplier's recommendations.
Microdissection, DNA and RNA isolation and LOH analy-
sis
High-molecular weight DNA from frozen tumor and the
corresponding peripheral blood specimens, and frozen
cells from cell lines was isolated as previously described
[25]. Tumor cells from paraffin-embedded CIN tissue
specimens were isolated by laser capture microdissection
(Arcturus, Mountain View, CA) after methyl green-stain-
ing and the extraction of DNA as described earlier [26].
Total RNA was isolated from semi-confluent cell cultures
using the TRIzol reagent (Life Technologies, Gaithersburg,
MD) according to the manufacturer's protocol. A panel of
20 sequence tagged repeat polymorphic (STRP) (18 di-
and two tetra-nucleotide) markers was chosen on the ba-
sis of their map position and heterozygosity (Fig. 1) (Gene
Map 99-  [http://www.ncbi.nlm.nih.gov/genemap]). A
standard polymerase chain reaction (PCR) containing
gamma [32P] ATP end-labeled forward primer, analysis of
PCR products on denaturing polyacrylamide sequencing
gels, and scoring of LOH on autoradiograms was per-
formed as previously described [25,26]. All autoradio-
grams were visually analyzed. Reduction of signal
intensity by 50% or more of one allele over the other al-
lele in tumor DNA compared with the intensity of consti-
tutional alleles was considered LOH. The definition of
minimal region of deletion was defined earlier [25]. The
LOH analysis was performed at least twice on all tumors
with the corresponding markers that define the minimal
deletions.
Detection of HPV types
The PGMY09/11 L1 consensus HPV L1 primers and re-
verse line blot hybridization system was used to detect 38
genital HPV types as described earlier [27,28]. Appropri-
ate control experiments were set up using bulk master mix
components to eliminate potential contamination. Indi-
vidual assay sensitivity was analyzed by the use of serial
dilutions of SiHa cell line crude cell digest, targeting 104,
103, 102, 101, and 100 input copies of HPV-16. A no tem-
plate negative control was set up in all experiments.
Analysis of gene expression
Total RNA isolated from the cell lines was reverse tran-
scribed using random primers and the Pro-STAR first
strand RT-PCR kit (Stratagene, La Jolla, CA). Semi-quanti-
tative analysis of gene expression was performed by 26 to
28 cycles of multiplex RT-PCR with -actin as control and
gene specific primers spanning at least 2 exons. The gene
primers used and their positions in cDNA were:
PDCD6-F 5'-GCTTCCTGTGGAACGTTTTC-3' (108–127
bp)
PDCD6-R 5'-TCTTATCGATCATCCCGGAG-3' (349–368
bp)
TERT-F 5'-GCGTTTGGTGGATGATTTCT-3' (2647–2666
bp)
TERT-R 5'-CAGGGCCTCGTCTTCTACAG-3' (2778–2797
bp)Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/3
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TRIP13-F 5'-CAGCAGCACTGCAAAGAAAG-3' (132–151
bp)
TRIP13-R 5'-TGTGAAGTGCAACAGTGCAT-3' (321–340
bp)
POLS-F 5'-CCCTTGTCCTGAAGAAGCAG-3' (43–62 bp)
POLS-R 5'-AGGACTTTGATGGAACACGG-3' (263–282
bp)
The PCR products were run on 1.5-% agarose gels, visual-
ized by ethidium bromide staining and quantitated using
the Kodak Digital Image Analysis System (Kodak, New
Haven, CT).
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